logo
I've been CURED of the deadliest form of brain cancer after being told I had months to live – I'm still here years later

I've been CURED of the deadliest form of brain cancer after being told I had months to live – I'm still here years later

The Sun5 days ago
A DAD given months to live after being diagnosed with the deadliest form of brain cancer saw his disease vanish - and his scans are still clear years later.
Most people with glioblastoma, an aggressive and fast growing type of brain tumour, don't live past 12 to 18 months.
6
6
The Wanted's Tom Parker died from the disease in March 2022.
Ben Trotman was diagnosed with glioblastoma in October 2022 at the age of 40, and brought his wedding forward after doctors said he'd likely live less than a year.
But he was cleared of cancer after being given a new drug called ipilimumab, as part of a breakthrough trial.
Well over two years later, Ben continues to show no signs of glioblastoma and his scans remain clear.
The now 43-year-old became a dad during that time is "focused on rebuilding the life he thought he had lost".
Now, the NHS has launched a new immunotherapy trial to treat the deadly brain cancer is seeking patients to take part in it.
The study - set up in memory of Baroness Margaret McDonagh, who died of the disease - will recruit 16 people over an 18-month period.
People diagnosed with glioblastoma will receive ipilimumab with immunotherapy, a type of cancer treatment that uses the immune system combat cancer cells.
They'll then undergo current standard treatment - which includes radiotherapy, chemotherapy and surgery - while their immune system is at its strongest.
The trial, ran by University College London Hospital's National Hospital for Neurology and Neurosurgery, follows a previous one for the same drug which closed due to lack of recruitment.
Man, 64, plays guitar while having a brain tumour
Consultant medical oncologist, Dr Paul Mulholland, who is leading the new trial and treated Ben said: "It is very unusual to have a clear scan with glioblastoma, especially when [Ben] didn't have the follow-up surgery that had been planned to remove all of the tumour that was initially visible on scans.
"We hope that the immunotherapy and follow-up treatment Ben has had will hold his tumour at bay - and it has so far, which we are delighted to see."
Ben got married to Emily two months after the immunotherapy treatment and in April, his daughter Mabel was born.
Emily said: "Getting this diagnosis was the most traumatic experience.
6
6
"We were grappling with the fact that Ben had gone from being apparently perfectly healthy to having months to live.
"Had we not met Dr Mulholland, that would have been it for us. We felt we had a lucky break in an otherwise devastating situation."
Ben went on to have the current standard treatment of radiotherapy and chemotherapy.
He has quarterly scans, which continue to be clear.
What are the symptoms of glioblastoma and how soon do they show?
Glioblastomas are the most common brain tumour in adults, while also being very aggressive and deadly.
Brain Tumour Research says tumours increase pressure in the skull, causing headaches.
Symptoms to look for are:
Headaches
Loss of appetite
Nausea and vomiting
Loss of balance
Mood swings
Problems speaking
Problems with memory or concentration
Seizures
Impaired vision
The symptoms can initially be quite non-specific, meaning they could be mistaken for lots of other conditions- even stress or a hangover.
The brain controls so many different functions that symptoms can vary greatly depending on where in the brain the tumour is.
Glioblastomas are very fast growing. Once found, experts can see them double within seven weeks.
But, according to Dr Stephen Bagley, assistant professor of medicine at Penn Medicine, the first spark of glioblastoma in the brain remains something of a mystery to medical experts.
One study concluded that a glioblastoma starts growing 330 days on average - almost a year - before a diagnosis.
Another found that there are changes in immune function up to five years before a diagnosis, with markers in blood samples - but symptoms only occur three months prior.
The dad said: "We obviously don't know what the future holds but having had the immunotherapy treatment and getting these encouraging scan results has given Emily and I a bit of hope.
"We are focused on rebuilding the life we thought we had lost and enjoying being parents."
Dame Siobhain McDonagh MP led a fundraising campaign to raise more than £1 million to cover the costs of the new trial.
6
6
Her sister, Baroness McDonagh, died from glioblastoma in 2023.
Dame Siobhain said: "My beloved sister Margaret was appalled to discover that there had been no advances in brain cancer treatment for decades when she was diagnosed with glioblastoma.
"Changing this was Margaret's final campaign and one that I have continued in her memory.
"I am so grateful to the many people who knew and respected Margaret who have come together and helped to raise funds and campaign for this new trial that we are calling Margaret's Trial."
Dr Mulholland said: "When I met Margaret she said to me 'what can I do to support you to cure this disease?'.
"I am incredibly grateful to her and to Siobhain whose campaigning and fundraising in her sister's memory has led to this new clinical trial opening for patients with this most aggressive form of brain cancer that has such a poor prognosis, with most patients surviving just nine months after diagnosis.
"The crucial element of this trial is that patients will have their immune system boosted by the drug before they have any other treatment, when they are fit and well enough to tolerate the immunotherapy.
"We're taking everything we have learned from previous trials into this new study and we are already planning follow-on trials.
"My aim is to find a cure for glioblastoma."
The National Brain Appeal is currently funding two posts in support of Dr Mulholland's research.
Treatment will take place at the NIHR UCLH's Clinical Research Facility and at the National Hospital for Neurology and Neurosurgery.
Patients interested in the new Win-Glio trial should discuss it with their consultant.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

UK-India trade deal sparks fears over access to cheap medicines for millions
UK-India trade deal sparks fears over access to cheap medicines for millions

ITV News

time5 minutes ago

  • ITV News

UK-India trade deal sparks fears over access to cheap medicines for millions

A newly signed trade agreement between India and the UK has triggered concerns that millions of poor Indians may lose access to affordable life-saving medicines. Civil society groups and health experts say the UK-India Free Trade Agreement (FTA), finalised between two countries, tilts the balance in favour of multinational pharmaceutical corporations and threatens to erode long-standing protections that have allowed India to produce low-cost generic drugs. 'This is not just about trade. It's about whether a person living on ₹200 (£2) a day can afford cancer treatment or survive tuberculosis,' said Jyotsna Singh, co-convenor of the Working Group on Access to Medicines and Treatments. At the heart of the controversy are the agreement's intellectual property (IP) provisions, which activists say may restrict the Indian government's ability to issue compulsory licences—legal tools that allow domestic companies to manufacture patented drugs at reduced prices during public health emergencies. India used this provision in 2012 to dramatically cut the price of sorafenib, a cancer drug sold by Bayer under the brand Nexavar. Generic versions slashed the monthly cost by nearly 97%, from ₹2.8 lakh (£2,600) to around ₹8,800 (£80), making it affordable to thousands. 'By discouraging compulsory licensing and promoting voluntary licences, the deal hands over control of access to medicines to the market,' said Prof Biswajit Dhar, a trade expert and former professor at New Delhi's Jawaharlal Nehru University. 'Voluntary licences often come with strings attached and don't bring the same price reductions.' Weakening India's Patent Safeguards Under the FTA, companies will no longer need to report annually how their patents are being 'worked'—or used—in India. Instead, disclosures can be made every three years, and some information can be kept confidential. Activists say this undermines transparency and makes it harder to prove that a drug isn't available to the public, a key step in applying for a compulsory licence. There are also concerns the deal could open the door to 'evergreening'—a tactic in which companies make minor changes to existing drugs and claim new patents. Indian law currently limits this practice under Section 3(d) of the Patents Act, but experts warn the FTA's emphasis on 'harmonisation' of IP standards with Western countries could override such protections. 'This is effectively a backdoor entry for TRIPS-plus provisions,' said K.M. Gopakumar, co-convenor of the Working Group. 'It would push India to grant unnecessary patents, prolonging monopolies and delaying cheaper alternatives.' The Indian pharmaceutical industry supplies more than 60% of global vaccines and a significant share of affordable generics to low- and middle-income countries. Critics say the FTA may limit this capacity and ultimately have consequences well beyond India's borders. Government response The Indian government has promoted the FTA as a landmark deal that will boost exports and attract UK investment in manufacturing, services, and digital trade. Officials insist that India has preserved its ability to protect public health. But rights groups remain unconvinced. 'You cannot negotiate away access to life-saving drugs in the name of free trade,' said Gargeya Telakapalli, a public health campaigner based in Hyderabad. 'The poorest Indians—those with cancer, HIV, diabetes, or TB—are being quietly sacrificed.' Broader implications The deal follows a similar agreement India signed last year with the European Free Trade Association (EFTA), which also faced criticism for diluting IP safeguards. Observers say the trend may reflect a shift in India's trade policy as it seeks closer ties with Western economies. But for many in India's healthcare and legal communities, the question remains: how much access to medicine is the country willing to give up for a better trade balance? From Westminster to Washington DC - our political experts are across all the latest key talking points. Listen to the latest episode below...

Health warning over counterfeit vodka made with medical-grade alcohol
Health warning over counterfeit vodka made with medical-grade alcohol

Metro

time35 minutes ago

  • Metro

Health warning over counterfeit vodka made with medical-grade alcohol

Health officials in Scotland have warned fans of Glen's vodka to keep an eye out for fake half bottles containing medical disinfectant. Scammers have hijacked the popular brand to sell counterfeit products containing the chemical isopropyl, which is typically used in hospital settings or in hand sanitiser. Food Standards Scotland (FSS) say the fake booze will smell and taste 'very different' to the Glen's product people recognise. Even small amounts of isopropyl can result in abdominal pain, vomiting, dizziness and headaches, they warned. Severe cases can leave drinkers in a coma or even dead. Genuine bottles of Glen's have a laser-etched code between the rear label and the base of the bottle which the fake bottles will not. More Trending Anyone concerned they might have drunk the counterfeit vodka, and who is experiencing symptoms, is urged to contact NHS 24 on 111 immediately. Glen's, one of the cheaper brands of vodka on the market, is a popular target for scammers. FSS has previously sent investigators to seize dozens of bottles of fake spirit using the same label from a shop in Coatbridge, Lanarkshire. And in September last year, the UK-wide Food Standards Agency sent out a warning about another fraud involving isopropyl alcohol in Glen's bottles. Get in touch with our news team by emailing us at webnews@ For more stories like this, check our news page. MORE: The one drink you should never order from a restaurant wine list MORE: How a generation-bending TikTok campaign saved a local boozer MORE: Forget about Prosecco — drink this £6.97 sparkling wine from Asda instead

NHS: Strike-hit appointments to be rebooked in two weeks but will impact others
NHS: Strike-hit appointments to be rebooked in two weeks but will impact others

The Independent

time35 minutes ago

  • The Independent

NHS: Strike-hit appointments to be rebooked in two weeks but will impact others

NHS England has said hospitals are aiming to reschedule appointments cancelled due to strikes within two weeks, but warned of knock-on impacts for other patients. Professor Meghana Pandit, NHS England's co-national medical director (secondary care), said that despite the five-day walkout by thousands of resident doctors in England, which began on Friday, local trusts have managed to maintain services with 'minimal disruption'. She told BBC Breakfast: 'If there's any rescheduling or postponement of surgery or appointments then the hospitals try their upmost best to get that appointment rescheduled within two weeks. 'I know it is distressing and even two weeks is too long for somebody to wait and actually that has an impact on the people who who are then displaced at that two week period.' Prof Pandit said there were three 'derogations' granted on Friday, a process which allows hospitals to request striking doctors return to work if there is a risk to patient safety. Nottingham City Hospital reached an agreement with the British Medical Association (BMA) to exempt one doctor from the strike to work on the neonatal intensive care unit. A derogation was agreed for one doctor in the emergency department and another doctor in the ISGM at the Northern General Hospital. The BMA said it had also agreed a derogation for two anaesthetists to work at University Hospital Lewisham on Saturday to ensure patient safety. It comes as Wes Streeting said 'we are doing everything we can to minimise' patient harm. The Health Secretary condemned the strike as 'reckless' and said the Government would not allow the BMA to 'hold the country to ransom'. Sir Keir Starmer made a last-minute appeal to resident doctors, saying the strikes would 'cause real damage'. He added: 'Most people do not support these strikes. They know they will cause real damage… 'These strikes threaten to turn back the clock on progress we have made in rebuilding the NHS over the last year, choking off the recovery.' The BMA has argued that real-terms pay has fallen by around 20% since 2008, and is pushing for full 'pay restoration'.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store